Show simple item record

dc.contributor.authorWareham, DWen_US
dc.contributor.authorBean, DCen_US
dc.date.accessioned2015-03-26T08:37:10Z
dc.date.available2006-04-21en_US
dc.date.issued2006-04-21en_US
dc.identifier.urihttp://qmro.qmul.ac.uk/xmlui/handle/123456789/7067
dc.description.abstractBACKGROUND: Acinetobacter baumannii has emerged as a major nosocomial pathogen worldwide. Many of the circulating strains exhibit multi-drug resistance remaining consistently susceptible only to polymyxins. In-vitro studies have reported that polymyxins combined with carbapenems, rifampicin or azithromycin are synergistic against these strains despite in-vitro resistance to these agents alone. The use of antimicrobial combinations have therefore been advocated for the treatment of severe A. baumannii infection in man. In order to determine whether such combinations are synergistic against the prevalent clones of multi-drug resistant A. baumannii causing infection in the UK, we performed synergy testing against representative isolates using two rapid Etest methods. METHODS: The activity of polymyxin in combination with imipenem, azithromycin or rifampicin was assessed against five strains of multi-drug resistant A. baumannii encoding OXA-23 carbapenemases. Synergy studies were performed by Etest-agar dilution and a combined Etest strip method. Synergy was defined as a FICI of < or = 0.5. RESULTS: All strains were resistant to beta-lactams, carbapenems, quinolones and aminoglycosides but susceptible to polymyxins. Marked synergy was not seen with polymyxin in combination with imipenem, rifampicin or azithromycin against any of the strains. Borderline synergy (FICI = 0.5) was seen against one strain belonging to OXA-23 clonal group 2, using the Etest-agar dilution method only. CONCLUSION: In-vitro synergy with polymxyin in combination with imipenem, rifampicin or azithromycin is highly strain and method dependent. As reliable synergy could not be demonstrated against the prevalent UK multi-drug resistant strains, use of such combinations should not be used for empirical treatment of these infections in the UK. The optimal treatment for serious multi-drug A. baumannii infection and the role of combination therapy should be addressed in a prospective clinical trial.en_US
dc.format.extent10 - ?en_US
dc.languageengen_US
dc.relation.ispartofAnn Clin Microbiol Antimicroben_US
dc.subjectAcinetobacter baumanniien_US
dc.subjectAnti-Bacterial Agentsen_US
dc.subjectAzithromycinen_US
dc.subjectDrug Resistance, Multiple, Bacterialen_US
dc.subjectDrug Synergismen_US
dc.subjectHumansen_US
dc.subjectImipenemen_US
dc.subjectMicrobial Sensitivity Testsen_US
dc.subjectPolymyxin Ben_US
dc.subjectRifampinen_US
dc.subjectbeta-Lactamasesen_US
dc.titleIn-vitro activity of polymyxin B in combination with imipenem, rifampicin and azithromycin versus multidrug resistant strains of Acinetobacter baumannii producing OXA-23 carbapenemases.en_US
dc.typeArticle
dc.identifier.doi10.1186/1476-0711-5-10en_US
pubs.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/16630352en_US
pubs.notesNot knownen_US
pubs.organisational-group/Queen Mary University of London
pubs.organisational-group/Queen Mary University of London/Faculty of Medicine & Dentistry
pubs.organisational-group/Queen Mary University of London/Faculty of Medicine & Dentistry/Blizard Institute
pubs.organisational-group/Queen Mary University of London/Faculty of Medicine & Dentistry/Blizard Institute/Immunobiology
pubs.organisational-group/Queen Mary University of London/REF
pubs.organisational-group/Queen Mary University of London/REF/REF - SMD - Blizard
pubs.publication-statusPublished onlineen_US
pubs.volume5en_US
dcterms.dateAccepted2006-04-21en_US


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record